Previous 10 | Next 10 |
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $200 (93% upside) price target at Berenberg. More news on: Summit Therapeutics plc, SpringWorks Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designati...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q4 2019 Earnings Call Feb 27, 2020 , 5:30 p.m. ET Operator Continue reading
Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Lauren Stival – Stern Investor Relations, Inc. Doug Fambrough – President and Chief Executive Officer Jack Green – Chief Financial Officer ...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q4 GAAP EPS of -$0.58 misses by $0.45 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Company Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative Programs; and Establishing New, High-Value Collaborations With Roche and Novo Nordisk A/S — — Ant...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2019 financial results after market close on Thursday, Feb. 27, 2020...
Investment Thesis I have been looking into the biotech sector for RNA interference ("RNAi") and in this article I am focusing on Dicerna Pharmaceuticals ( DRNA ). Despite competing in a crowded field, the company's recent collaboration deals are impressive and there is reason to believe the ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...